PDL BioPharma, Inc. (PDLI) Files An 8-K Other Events
Item 8.01 Other Events.
On November 15, 2016, PDL BioPharma, Inc. (the Company) issued a
press release announcing that it intends to offer, subject to
market and other conditions, $150 million aggregate principal
amount of new convertible senior notes due December 1, 2021
(Notes) under the Companys shelf registration statement filed
with the U.S. Securities and Exchange Commission on June 10,
2016. The Company also expects to grant the underwriters a 12-day
overallotment option to purchase up to an additional $22.5
million aggregate principal amount of notes on the same terms and
conditions. The press release is attached hereto as Exhibit 99.1
and is incorporated herein by reference. The Company is also
filing the investor presentation slides attached hereto as
Exhibit 99.2 and is incorporated herein by reference, which
presentation the Company intends to use in conversations with
prospective investors.
press release announcing that it intends to offer, subject to
market and other conditions, $150 million aggregate principal
amount of new convertible senior notes due December 1, 2021
(Notes) under the Companys shelf registration statement filed
with the U.S. Securities and Exchange Commission on June 10,
2016. The Company also expects to grant the underwriters a 12-day
overallotment option to purchase up to an additional $22.5
million aggregate principal amount of notes on the same terms and
conditions. The press release is attached hereto as Exhibit 99.1
and is incorporated herein by reference. The Company is also
filing the investor presentation slides attached hereto as
Exhibit 99.2 and is incorporated herein by reference, which
presentation the Company intends to use in conversations with
prospective investors.
Item 9.01 Financial Statements and Exhibits.
(d) Exhibits
|
Exhibit No.
|
Description
|
|
|
99.1
|
Press Release
|
|
|
99.2
|
Investor Presentation
|
>
About PDL BioPharma, Inc. (PDLI)